Drug target ontology to classify and integrate drug discovery data
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: One of the most successful approaches to develop new small molecule therapeutics has been to start from a validated druggable protein target. However, only a small subset of potentially druggable targets has attracted significant research and development resources. The Illuminating the Druggable Genome (IDG) project develops resources to catalyze the development of likely targetable, yet currently understudied prospective drug targets. A central component of the IDG program is a comprehensive knowledge resource of the druggable genome. RESULTS: As part of that effort, we have developed a framework to integrate, navigate, and analyze drug discovery data based on formalized and standardized classifications and annotations of druggable protein targets, the Drug Target Ontology (DTO). DTO was constructed by extensive curation and consolidation of various resources. DTO classifies the four major drug target protein families, GPCRs, kinases, ion channels and nuclear receptors, based on phylogenecity, function, target development level, disease association, tissue expression, chemical ligand and substrate characteristics, and target-family specific characteristics. The formal ontology was built using a new software tool to auto-generate most axioms from a database while supporting manual knowledge acquisition. A modular, hierarchical implementation facilitate ontology development and maintenance and makes use of various external ontologies, thus integrating the DTO into the ecosystem of biomedical ontologies. As a formal OWL-DL ontology, DTO contains asserted and inferred axioms. Modeling data from the Library of Integrated Network-based Cellular Signatures (LINCS) program illustrates the potential of DTO for contextual data integration and nuanced definition of important drug target characteristics. DTO has been implemented in the IDG user interface Portal, Pharos and the TIN-X explorer of protein target disease relationships. CONCLUSIONS: DTO was built based on the need for a formal semantic model for druggable targets including various related information such as protein, gene, protein domain, protein structure, binding site, small molecule drug, mechanism of action, protein tissue localization, disease association, and many other types of information. DTO will further facilitate the otherwise challenging integration and formal linking to biological assays, phenotypes, disease models, drug poly-pharmacology, binding kinetics and many other processes, functions and qualities that are at the core of drug discovery. The first version of DTO is publically available via the website http://drugtargetontology.org/ , Github ( http://github.com/DrugTargetOntology/DTO ), and the NCBO Bioportal ( http://bioportal.bioontology.org/ontologies/DTO ). The long-term goal of DTO is to provide such an integrative framework and to populate the ontology with this information as a community resource.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bostock, M., Ogievetsky, V., & Heer, J. (2011) · IEEE Transactions on Visualization and Computer Graphics · doi:10.1109/tvcg.2011.185 · Cited by 3,165
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Self-citationDISEASES: Text mining and data integration of disease–gene associations
Pletscher-Frankild, S., Pallejà, A., Tsafou, K., Binder, J. X., & Jensen, L. J. (2015) · Methods · doi:10.1016/j.ymeth.2014.11.020 · Cited by 591
Self-citationDrugCentral: online drug compendium
Ursu, O., Holmes, J., Knockel, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Nelson, S. J., & Oprea, T. I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw993 · Cited by 323 · cited 2×
“In some cases, targets have been manually migrated to Tchem through human curation, based on small molecule activities from sources other than ChEMBL or DrugCentral [34].”
MethodSelf-citationPharos: collating protein information to shed light on the druggable genome
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1072 · Cited by 279
Self-citationKoleti, A., Terryn, R., Stathias, V., Chung, C., Cooper, D. J., Turner, J. P., Vidović, D., Forlin, M., Kelley, T. T., D’Urso, A., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1063 · Cited by 193
Self-citationTIN-X: target importance and novelty explorer
Cannon, D. C., Yang, J. J., Mathias, S. L., Ursu, O., Mani, S., Waller, A., Schürer, S. C., Jensen, L. J., Sklar, L. A., Bologa, C. G., et al. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx200 · Cited by 34
Self-citation
Cited by
Rethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894
“Another challenge to annotation is the rapidly changing and inconsistently described landscape of biology, that is, the lack of a coherent ontology 31,32 .”
BackgroundUnexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
Self-citationAn intelligent healthcare monitoring framework using wearable sensors and social networking data
Ali, F., El-Sappagh, S., Islam, S. M. R., Ali, A., Attique, M., Imran, M., & Kwak, K.-S. (2021) · Future Generation Computer Systems · doi:10.1016/j.future.2020.07.047 · Cited by 355
Erratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
Self-citationMachine and deep learning approaches for cancer drug repurposing
Issa, N. T., Stathias, V., Schürer, S., & Dakshanamurthy, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.011 · Cited by 274
Self-citation
Metadata
- Authors
- Lin, Y., Mehta, S., Küçük-McGinty, H., Turner, J. P., Vidovic, D., Forlin, M., Koleti, A., Nguyen, D.-T., Jensen, L. J., Guha, R., Mathias, S. L., Ursu, O., Stathias, V., Duan, J., Nabizadeh, N., Chung, C., Mader, C., Visser, U., Yang, J. J., Bologa, C. G., Oprea, T. I., & Schürer, S. C.
- Venue
- Journal of Biomedical Semantics
- Published
- 2017-11-09
- Volume
- 8
- Issue
- 1
- Pages
- 50-50
- ISSN
- 2041-1480 (ISSN-L)
- OpenAlex
- W2952200877
- Cited by
- 69
- References
- 7
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug target ontology to classify and integrate drug discovery data. https://app.cochat.ai/papers/10.1186/s13326-017-0161-x
- The paper
- Lin, Y., Mehta, S., Küçük-McGinty, H., Turner, J. P., Vidovic, D., Forlin, M., Koleti, A., Nguyen, D.-T., Jensen, L. J., Guha, R., Mathias, S. L., Ursu, O., Stathias, V., Duan, J., Nabizadeh, N., Chung, C., Mader, C., Visser, U., Yang, J. J., . . . Schürer, S. C. (2017). Drug target ontology to classify and integrate drug discovery data. Journal of Biomedical Semantics. https://doi.org/10.1186/s13326-017-0161-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.